Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) launch direct-to-patient Eliquis program

Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced a direct-to-patient purchase option for Eliquis through their Eliquis 360 Support program, offering the blood thinner at more than 40% below current list price.

Beginning September 8, eligible U.S. patients with an Eliquis prescription can purchase the medication directly through the program with shipping to all 50 states and Puerto Rico. The program targets uninsured, underinsured, or self-pay patients seeking to reduce out-of-pocket costs.

“This program passes more savings directly to patients and demonstrates our continued focus on identifying innovative solutions that foster the best outcomes for each individual while prioritizing access to care,” said Christopher Boerner, board chair and CEO of Bristol Myers Squibb, according to the press release.

Eliquis, an oral anticoagulant, is used to reduce stroke risk in patients with atrial fibrillation and treat blood clots. The companies state that more than 15 million Americans have been prescribed the medication since its launch.

The Eliquis 360 Support program currently provides health education and helps patients navigate prescription insurance coverage. The new direct-purchase option expands the program’s services to include medication sales with transparent pricing.

The announcement comes as pharmaceutical companies face increasing pressure to improve drug affordability and access. The program allows patients to bypass traditional pharmacy channels and insurance coverage limitations.